# Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses

> **NCT03620032** · PHASE2 · UNKNOWN · sponsor: **Fondazione IRCCS Istituto Nazionale dei Tumori, Milano** · enrollment: 54 (actual)

## Conditions studied

- Diffuse Intrinsic Pontine Glioma

## Interventions

- **DRUG:** Nimotuzumab
- **DRUG:** Vinorelbine
- **OTHER:** Radiotherapy

## Key facts

- **NCT ID:** NCT03620032
- **Lead sponsor:** Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-11-02
- **Primary completion:** 2022-11-11
- **Final completion:** 2024-11-02
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2023-12-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03620032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03620032, "Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03620032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*